Top Cancer Drug Linked to Heart Problems

The world’s top-selling cancer drug has suffered another setback.

A new study published in the Journal of Clinical Oncology found that women treated with Avastin for breast cancer were more likely to develop heart failure.

The research team, led by Dr. Toni Choueiri of the Dana Farber Cancer Institute and Harvard Medical School, found that 1.6 percent of the women who took Avastin, or bevacizumab, developed congestive heart failure. That compared with 0.4 percent of women who received a placebo.

“Overall, the risk is small, but it is definitely more than the placebo,” Choueiri said in a telephone interview with Reuters.

The conclusions were based on the analysis of five clinical trials involving nearly 4,000 women with advanced breast cancer.

In December, the U.S. Food and Drug Administration took a first step toward revoking the approval of Avastin for treating breast cancer, saying that recent research failed to provide evidence it was helping patients. The drug, which is made by Genentech, remains approved, however, for treating colorectal, lung, kidney and brain cancers.

Related Post:
FDA Advises Against Avastin as a Cancer Treatment

Print Print  

Like what we're doing? We'd appreciate your support.

Leave a comment